Most Read Articles
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

5 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 4 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

TKIs less effective in lung cancer patients with complex EGFR mutations and primary drug-resistance patterns

Christina Lau
02 May 2018

First-generation EGFR tyrosine kinase inhibitor (TKI) therapy is less effective in patients with advanced lung adenocarcinoma who have complex EGFR mutations and primary drug-resistance patterns, according to results of a Chinese study reported at ELCC 2018.

The retrospective study included 5,898 patients diagnosed with EGFR mutation–positive lung adenocarcinoma between January 2011 and January 2017. Complex EGFR mutations (eg, two or more different EGFR mutations within a tumour sample) were identified in 187 patients (3.2 percent), 95 of whom had advanced lung adenocarcinoma and were treated with EGFR TKIs. [Zhang B, et al, ELCC 2018, abstract 140PD]

“Among 27 patients with Del-19+21L858R mutations, the objective response rate [ORR] with standard first-generation EGFR TKI therapy was 72.7 percent. The ORR in patients with Del-19/21L858R+ atypical mutation [n=28] and those with double atypical mutations [n=20] was 54.2 percent and 66.7 percent, respectively,” reported investigator Dr Bo Zhang of the Shanghai Chest Hospital in Shanghai, China.

Median progression-free survival (PFS) was also the longest in patients with Del-19+21L858R mutations, at 18.2 months. In patients with Del-19/21L858R+ atypical mutation and those with double atypical mutations, median PFS was 10.1 months and 11.1 months, respectively.

“These findings suggest that standard first-generation EGFR TKI therapy is effective in patients with Del-19+21L858R mutations, Del-19/21L858R+ atypical mutation and double atypical mutations,” said Zhang.

“The poorest response was seen in patients with complex EGFR mutations and primary drug-resistance patterns [n=20]. In these patients, the ORR was 15 percent, and median PFS was just 1.4 months,” Zhang continued.

“The prevalence of complex EGFR mutations in patients with lung adenocarcinoma was previously undocumented. Whether the presence of complex mutations would alter the efficacy of standard first-line EGFR TKI therapy had also remained unknown,” he added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

5 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 4 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.